Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emi Noguchi

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Oncology|April 4, 2018
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous TumorTakahiro Ebata, Tatsunori Shimoi, Seiko Bun, et al.
BMC Cancer|January 14, 2022
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective studyShigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, et al.
Medicine|September 22, 2020
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatmentRurina Watanuki, Akihiko Shimomura, Shu Yazaki, et al.
Anti-Cancer Drugs|November 28, 2017
A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulinChiaki Inagaki, Tatsunori Shimoi, Hitomi Okuma, et al.
ESMO Open|August 2, 2017
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancerAtsuko Kitano, Makiko Ono, Masayuki Yoshida, et al.
BMC Cancer|October 21, 2021
Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancersTatsunori Shimoi, Jun Hashimoto, Kazuki Sudo, et al.
Breast Cancer (Tokyo, Japan)|December 10, 2017
TERT promoter hotspot mutations in breast cancerTatsunori Shimoi, Masayuki Yoshida, Yuka Kitamura, et al.
Oncology|February 4, 2025
Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing TestRumi Nishimura, Kazuki Sudo, Rui Kitadai, et al.
BMC Cancer|April 15, 2022
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective studyShigemasa Takamizawa, Tatsunori Shimoi, Masayuki Yoshida, et al.
Breast Cancer (Tokyo, Japan)|August 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabineRui Kitadai, Tatsunori Shimoi, Shu Yazaki, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Oncology|April 4, 2018
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous TumorTakahiro Ebata, Tatsunori Shimoi, Seiko Bun, et al.
BMC Cancer|January 14, 2022
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective studyShigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, et al.
Medicine|September 22, 2020
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatmentRurina Watanuki, Akihiko Shimomura, Shu Yazaki, et al.
Anti-Cancer Drugs|November 28, 2017
A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulinChiaki Inagaki, Tatsunori Shimoi, Hitomi Okuma, et al.
ESMO Open|August 2, 2017
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancerAtsuko Kitano, Makiko Ono, Masayuki Yoshida, et al.
BMC Cancer|October 21, 2021
Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancersTatsunori Shimoi, Jun Hashimoto, Kazuki Sudo, et al.
Breast Cancer (Tokyo, Japan)|December 10, 2017
TERT promoter hotspot mutations in breast cancerTatsunori Shimoi, Masayuki Yoshida, Yuka Kitamura, et al.
Oncology|February 4, 2025
Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing TestRumi Nishimura, Kazuki Sudo, Rui Kitadai, et al.
BMC Cancer|April 15, 2022
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective studyShigemasa Takamizawa, Tatsunori Shimoi, Masayuki Yoshida, et al.
Breast Cancer (Tokyo, Japan)|August 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabineRui Kitadai, Tatsunori Shimoi, Shu Yazaki, et al.
Pageof 6